Iadademstat in combination with azacitidine generates robust and long lasting responses in AML Patients (ALICE Trial)
Authors
Salamero, O.Somervaille, Tim C P
Molero, A.
Acuna-Cruz, E.
Perez-Simon, J.
Coll, R.
Sangerman, M. A.
Merchan, B.
Perez, A.
Cano, I.
Rodriguez-Veiga, R.
Gutierrez, S.
Buesa, C.
Bosch, F.
Montesinos, P.
Affiliation
Department of Hematology, Vall d'Hebron University Hospital. Experimental Hematology Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SpainIssue Date
2021
Metadata
Show full item recordCitation
Salamero O, Somervaille TCP, Molero A, Acuna-Cruz E, Perez-Simon J, Coll R, et al. Iadademstat in Combination with Azacitidine Generates Robust and Long Lasting Responses in AML Patients (ALICE Trial). Blood. 2021 Nov;138. PubMed PMID: WOS:000736413905193.Journal
BloodDOI
10.1182/blood-2021-152183Additional Links
https://dx.doi.org/10.1182/blood-2021-152183Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2021-152183